Edwards Larry Todd 4

4 · Arcutis Biotherapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 5, 2026

Arcutis (ARQT) EVP Larry T. Edwards Sells 2,052 Shares

What Happened

Larry T. Edwards, Executive Vice President & Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), sold 2,052 shares on 2026-02-02 in an open-market transaction. The reported weighted-average sale price was $25.50, for total proceeds of approximately $52,323. The sale was to cover tax withholding tied to the vesting of RSUs granted January 12, 2024.

Key Details

Transaction date: February 2, 2026; Form filed February 4, 2026 (timely filing).
Price: weighted average $25.50; individual trade prices ranged $24.745 to $25.68. (Reporting person can provide per-trade breakdown on request.)
Reason: Sale to satisfy tax withholding obligation related to vesting of restricted stock units (RSUs).
Shares owned after transaction: Not specified in the provided filing.
Additional note: Footnote indicates holdings include 724 shares purchased under the company's Employee Stock Purchase Plan on 2025-11-30.

Context

This was a tax-withholding sale tied to RSU vesting (routine administrative sale), not an independent judgment to reduce or increase exposure to the stock. Such sales are common when shares vest and the employer or insider sells a portion to cover withholding taxes.

Form 4

Period: 2026-02-02

See Remarks

Transactions

Footnotes (3)

[F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.
[F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F3]Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025.

Signature

/s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards|2026-02-04

1 file